

**Sun Pharmaceutical Industries Ltd.**

Sun House, Plot No. 201 B/1,  
Western Express Highway,  
Goregaon (East), Mumbai – 400063 India  
Tel. : (91-22) 43244324 / 1234  
Fax.: (91-22) 43244343  
CIN: L24230GJ1993PLC019050, www.sunpharma.com



January 18, 2019

**National Stock Exchange of India Ltd,**

Exchange Plaza, 5th Floor,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (East), Mumbai – 400 051.

**NSE Code – SUNPHARMA**

**BSE Ltd,**

Market Operations Dept.  
P. J. Towers, Dalal Street,  
Mumbai - 400 001.

**BSE Code– 524715**

Sub: Our letter to SEBI on a media report regarding alleged second whistleblower complaint filed against our Company

Dear Sirs,

We are enclosing herewith our letter, dated January 18, 2019, sent today to The Chairman, Securities and Exchange Board of India (SEBI) on a media report regarding alleged second whistleblower complaint filed against our Company.

This is for your information and records.

Yours faithfully,

**For Sun Pharmaceutical Industries Limited,**

A handwritten signature in blue ink, appearing to read "Sunil Ajmera", with a horizontal line underneath.

**Sunil Ajmera**  
**Company Secretary**

**Enclosures: As above**

Sun Pharmaceutical Industries Ltd.  
Sun House, Plot No. 201 B/1,  
Western Express Highway,  
Goregaon (East), Mumbai – 400063 India  
Tel. : (91-22) 43244324 / 1234  
Fax.: (91-22) 43244343  
CIN: L24230GJ1993PLC019050, www.sunpharma.com



January 18, 2019

The Chairman,  
Shri Ajay Tyagi  
Securities and Exchange Board of India,  
Plot No.C4-A, 'G' Block  
Bandra-Kurla Complex, Bandra (East),  
Mumbai - 400051, Maharashtra

Sub: Media report regarding alleged second whistleblower complaint filed against our Company

Dear Sir,

We wish to bring to your kind notice an alleged second whistleblower complaint filed against our Company, which we learnt from a media report on January 15, 2019 (<https://www.moneylife.in/article/new-172-page-whistleblower-complaint-to-sebl-documents-sun-pharmas-nexus-with-aditya-medisales-i/56123.html>). We also learnt on November 30, 2018, from a media report that a whistleblower complaint was filed against the company.

The said whistleblower documents and other confidential emails are being offered for inspection to institutional investors by one media house as per the above report, which again we are not privy to.

In these circumstances, there is a great asymmetry in the information circulating between analysts, investors and media leading to intense speculation. The availability of information contained in the whistleblower documents to a set of selective investors does put other investors including retail investors in a disadvantageous position. We are concerned that certain entities/individuals are adopting unfair trade practices prejudicial to the interest of shareholders and other stakeholders. It is evident from the fact that shareholders value has been drastically eroded within a short span of time due to unsubstantiated complaint/allegation against the company and mala fide campaign launched by certain media houses.

We request your office to examine the matter in its entirety, and the role of some media houses and other stakeholders.

**For Sun Pharmaceutical Industries Limited,**

A handwritten signature in blue ink, appearing to read "Sunil Ajmera", with a horizontal line underneath.

**Sunil Ajmera**  
**Company Secretary**